{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:19:50Z","timestamp":1787959190617,"version":"build-2784847793"},"reference-count":0,"publisher":"MyJove Corporation","issue":"234","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoVE"],"DOI":"10.3791\/71790","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:00:26Z","timestamp":1787958026000},"source":"Crossref","is-referenced-by-count":0,"title":["Evaluating Combined Sorafenib and Gemcitabine Treatment in HepG2 Cells and a NOD\/SCID Mouse Xenograft Model: A Pilot Study"],"prefix":"10.3791","author":[{"given":"Qing-Qing","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu-Jin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nai-Tao","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao-Lian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai-Wei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2098","published-online":{"date-parts":[[2026,8,28]]},"container-title":["Journal of Visualized Experiments"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jove.com\/t\/71790\/evaluating-combined-sorafenib-gemcitabine-treatment-hepg2-cells","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:00:26Z","timestamp":1787958026000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jove.com\/t\/71790\/evaluating-combined-sorafenib-gemcitabine-treatment-hepg2-cells"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":0,"journal-issue":{"issue":"234","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.3791\/71790","relation":{},"ISSN":["1940-087X"],"issn-type":[{"value":"1940-087X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]}}}